Healthcare / BiotechnologyNasdaqCM
$19.24
+0.17 (+0.89%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-30.8M · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$394M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-113.7%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2015–2025 · 10 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.74x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-69.4M · FCF $-51.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||
| Revenue | — | — | — | — | — | — | — | $36000.00 | $18.0M | $41000.00 | $49000.00 | — |
| Net Income | $-69.4M | $-69.4M | $-35.5M | $-31.5M | $-13.9M | $-21.7M | $-46.5M | $-4.1M | $-49.0M | $-38.9M | $-33.5M | $-23.1M |
| EBITDA | $-70.6M | $-70.6M | $-36.6M | $-32.5M | $-13.9M | — | — | — | — | — | — | — |
| EPS | -4.71 | -4.71 | -12.17 | -24.92 | -20.00 | -38.75 | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | -11288.9% | -254.2% | -91775.6% | -64673.5% | — |
| Net Margin | — | — | — | — | — | — | — | -11302.8% | -271.4% | -94948.8% | -68322.4% | — |
| Balance Sheet | ||||||||||||
| Debt/Equity | — | — | — | — | — | — | — | — | -35.60 | 0.05 | -0.08 | — |
| Current Ratio | 2.75 | 2.75 | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||
| Free Cash Flow | $-51.0M | $-51.0M | $-30.8M | $-28.8M | $-8.2M | — | — | $-2.9M | $-36.4M | $-31.8M | $-30.1M | — |
| Returns | ||||||||||||
| ROE | -113.7% | -113.7% | -67.6% | -89.1% | -35.8% | -52.2% | -78.8% | 85.3% | 6651.5% | -54.8% | 26.9% | 25.0% |
| Valuation | ||||||||||||
| P/B | 4.64 | 4.64 | 1.36 | 0.74 | 0.45 | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||
| Revenue Growth | — | — | — | — | — | — | — | -99.8% | 43890.2% | -16.3% | — | — |
| EPS Growth | 61.3% | 61.3% | 51.2% | -24.6% | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+126.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-12.17 → -4.71
Residual
+126.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.